Mapping Pathways is a multi-national project to develop and nurture a research-driven, community-led global understanding of the emerging evidence base around the adoption of antiretroviral-based prevention strategies to end the HIV/AIDS epidemic. The evidence base is more than results from clinical trials - it must include stakeholder and community perspectives as well.

13 July 2011

New Studies Show PrEP Works for Heterosexuals Too

via Aidsmap, by Keith Alcorn

Two large studies of pre-exposure prophylaxis – use of antiretroviral drugs by uninfected people to prevent HIV infection – have shown that taking tenofovir or tenofovir plus emtricitabine (Truvada) can cut the risk of HIV infection through sexual transmission by between 62% and 73% in male-female couples. Results from both the Partner study and the TDF2 study were released today.

“This study demonstrates that antiretrovirals are a highly potent and fundamental cornerstone for HIV prevention and should become an integral part of global efforts for HIV prevention,” said Dr Connie Celum, Professor of Global Health and Medicine at the University of Washington, Seattle.

The results, released this morning ahead of the International AIDS Society conference in Rome next week, follow positive results from the IPrEX study of Truvada PrEP in men who have sex with men released in November 2010.

Fuller results from the studies will be presented next week.

Read the rest.

[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

No comments:

Post a Comment